According to researchers, most states are violating federal laws by denying coverage for Sovaldi, as well as ignoring scientific evidence, treatment guidelines and clinical data.
The high cost of hepatitis C treatment has inspired lawsuits and protests. Now, activist have targeted the hedge fund investors who they say are reaping profits from the pricey pills. Rod McCullom reports.
How does pharmaceutical company math work? One activist takes Gilead to task for the price of its next hepatitis C drug.
In just the past month, a pair of drugs were approved that may forever change (for the better!) the way hepatitis C is treated. But as treatment advocate George Carter laments, the revolution may come at too high a price.
The Fair Pricing Coalition (FPC) today condemned Gilead Sciences for the price set for its direct acting antiviral (DAA) Sovaldi™ (sofosbuvir), a once-daily, first-in-class nucleotide polymerase inhibitor approved by the U.S. Food and Drug Administra...